On March 15, Chengdu Tianfu international biological city reported another success. Recently, the covid-19 virus antigen self-test product launched by Maccura Biotechnology Co.Ltd(300463) (hereinafter referred to as ” Maccura Biotechnology Co.Ltd(300463) “) has been registered in Australia and officially entered the Australian medical supplies registration list (ARTG No. 385370). Previously, Maccura Biotechnology Co.Ltd(300463) covid-19 virus antigen detection reagent has also obtained multiple verifications from European Union CE, German bfarm and other multinational authorities.
It is understood that Maccura Biotechnology Co.Ltd(300463) is simultaneously carrying out the registration and application of covid-19 antigen detection reagent for medical and household use in China. In addition, the first generation of recombinant New Coronavirus vaccine (Sf9 cell) of the world’s bio city enterprise in the Tianfu international bio city is about to complete the global multi phase III clinical trial. Nearly 40 thousand participants have been vaccinated and vaccinated. The clinical trials have been completed in Japan for conditional listing. The results of clinical trials show that the vaccine has good safety and immunogenicity.
On March 14 this year, Chengdu Tianfu international biological city entered its seventh year of development. It not only gave birth to biomedical related enterprises that made great efforts in covid-19 vaccine research and development, but also preliminarily established a biological industry ecosystem with international competitiveness and regional driving force. There are 170 settled projects with a total investment of more than 110 billion yuan and 4 national academician teams, 51 high-level talent teams with more than 2000 professionals; It has gathered 134 varieties of pharmaceutical machinery and introduced 99 functional platforms in total; 43 projects have been completed, including Yongan blood preparation phase I of Tianfu biological city, BOE digital medical center and Nuofeng international preparation production base, and 9 square kilometers of compound space for production, life and ecology has been developed.
many enterprises have made efforts to tackle key innovative technologies, and five enterprises have successfully listed
The reporter learned from Chengdu Tianfu international biological city that Maccura Biotechnology Co.Ltd(300463) is further increasing its investment in research and development in the biological city. In March last year, Maccura Biotechnology Co.Ltd(300463) ivd Industrial Park project laid the foundation in the biological city and is now under accelerated construction.
It is reported that Maccura Biotechnology Co.Ltd(300463) Tianfu international biological city IVD Industrial Park project plans to build a number of production lines including blood cell diagnostic reagents, coagulation diagnostic reagents, blood group diagnostic reagents, blood glucose test strips, colloidal gold detection, other blood diagnostic reagents and cleaning fluids, and is committed to R & D and production, including key innovative technologies Innovative varieties of medical devices that have reached the international advanced level and have good market prospects.
Earlier, Maccura Biotechnology Co.Ltd(300463) chairman Tang Yong said publicly that Chengdu Tianfu international biological city is a high-tech biological industry integration place integrating industry, innovation, talents, finance and other policy advantages, and also a source of global biomedical innovation in the future. The clustering of high-tech biological industries will provide a better ecological environment for the development of Mike.
After six years of development, the development of enterprises related to biological city has made remarkable achievements. On March 14, Chengdu Olymvax Biopharmaceuticals Inc(688319) the first batch of nearly 70000 doses of export adsorbed tetanus vaccine was shipped and will arrive overseas in the near future. The export sales of adsorbed tetanus vaccine is the first time that Chengdu Olymvax Biopharmaceuticals Inc(688319) achieved product export sales, which is a milestone in the development history of the company.
It is reported that Chengdu Olymvax Biopharmaceuticals Inc(688319) is one of the five listed companies promoted by Chengdu Tianfu international biological city. The other four enterprises are pilot drugs, Chengdu Easton Bio Pharmaceuticals Co.Ltd(688513) , conoya and Haichuang pharmaceutical.
continuously improve industrial competitive advantage and build a collaborative and efficient Bio Industry Ecosystem
As the country’s first pilot demonstration base for the transfer and transformation of major national scientific and technological special achievements in the creation of major new drugs, Chengdu Tianfu international biological city has gathered 134 varieties of drug research equipment, undertaken 879 new drug achievement transfer and transformation services, and supported the application of 89 new drug varieties such as dangefenone capsule in China or internationally, Support Sichuan Huiyu Pharmaceutical Co.Ltd(688553) oxaliplatin and other 52 varieties to obtain new drug certificates or production approvals; A total of 119 class 1 new drugs are under development, ranking in the forefront of national biomedical parks, of which about half have entered the stage of clinical trials.
In the core area of the 1 square kilometer biological science and Technology Innovation Park, it has successively introduced 99 functional platforms, including 6 national platforms, including the first national demonstration platform for the transfer and transformation of health scientific and technological achievements, and successfully built a professional outsourcing “one-stop” service platform system covering the whole chain from target discovery to product listing, Enterprises in each industrial field can start a business with their bags, which greatly reduces the start-up cost.
In addition to the innovation chain, the industrial chain, factor chain, supply chain and value chain of Chengdu Tianfu international biological city have developed. Up to now, 170 bio city projects have been settled, with a total investment of more than 110 billion yuan, including a number of world top 500 projects such as Sinopharm Zhongsheng blood products headquarters and industrial base, semefeld international bio city joint innovation laboratory and so on. A total of 43 projects including BOE digital medical center and Nuofeng international preparation production base have been completed.
In addition, Chengdu Tianfu international biological city has promoted Chengdu to become the fourth port in China with the ability of bonded import of biological products after Beijing, Shanghai and Guangzhou. It has completed the customs clearance of human albumin in killiford and jetbelin, and successfully realized the first bonded logistics mode of importing biological products in the province.
comprehensively improve the livable quality of the city and create a convenient and comfortable life circle for entrepreneurs
While building a strong circle and chain, the urban function of Chengdu Tianfu international biological city is also constantly improving.
Norbo kindergarten, Wanhui primary school, BOE hospital, talent apartment and other public service supporting facilities have jointly built a life circle with balanced work and living and convenient living in the biological city. Yongan Lake Urban Forest Park in the biological city has successfully held various events such as China open 2021 China boat fishing (Luya) open promotion competition, and won the first “Sichuan Youth Sports Federation winter and summer camp” in the province.
At present, Chengdu Tianfu international biological city has two urban parks, two cultural centers, a conference center, a complex, a commercial street and a resettlement community with a total area of about 1 million square meters. Nearly 30 commercial projects have been signed, covering nearly 10000 employees of enterprises in the park and surrounding residents, forming a commercial consumption scene of food, housing, travel, shopping and entertainment.
In the future, Chengdu Tianfu international biological city will adhere to the integration of industry and city and the balance between work and residence, plan and build living service facilities, improve the livability and industry level of the park, and organically connect the park community, Incubation Park, park in park and residential area by relying on Shuangquan house of Yong’an lake, business street of Incubation Park, BOE Information Industry Park and qingcuili business street, Build a comfortable and convenient integrated life circle in the biological city.
The relevant person in charge of Chengdu Tianfu international biological city said that with the goal of continuously maintaining the comprehensive competitiveness of the biomedical park in the first echelon of the country, it will create the optimal investment environment, improve the economic benefits of urban development, strive to build a biological industry growth pole and Beijing Dynamic Power Co.Ltd(600405) , which will be integrated into the construction of Chengdu Chongqing double city economic circle, and promote the leapfrog development of Chengdu biomedical industry, We will strive to achieve a total output of more than 500 billion, a new population of more than 200000 and more than 30000 enterprises by 2035.
